Measuring treatment effect in acute stroke trials [6]

Stroke

Volumn 37, Issue 9, 2006, Pages 2204-

  Khatri, Pooja ^a   Broderick, Joseph ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

CLINICAL TRIAL; GLASGOW COMA SCALE; HUMAN; LETTER; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; STROKE; THERAPY; TREATMENT OUTCOME; VALIDATION PROCESS;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); TREATMENT OUTCOME;

EID: 33748346015     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000237182.54763.59     Document Type: Letter

References (4)

1. Bruno A, Saha C, Williams LS. Using change in the National Institutes of Health Stroke Scale to measure treatment effect in acute stroke trials. Stroke. 2006;37:920-921.
2. Broderick JP, Lu M, Kothari R, Levine SR, Lyden PD, Haley EC, Brott TG, Grotta J, Tilley BC, Marler JR, Frankel M. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke. 2000;31:2335-2341.
3. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke. 2004;35:904-911.
4. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW, Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.